PDCD1 and melanoma: In the B16 melanoma model, the dual depletion of LAG-3 and PD-1 on TILs reduced tumor-induced tolerance and achieved higher response rates compared to single-checkpoint deficient mice, with an 80% tumor elimination rate compared to 40% in PDCD1-deficient mice and no control in wild-type and LAG-3-deficient mice.